Hemab Therapeutics Stock

hemab.comHealthcare / BioTech & PharmaFounded: 2022

Hemab Therapeutics, founded in 2019, specializes in developing treatments for patients with bleeding and thrombotic disorders. Specifically, the company focuses on finding preventive treatments for less-common disorders for which fewer treatments are currently available. The company’s therapies are designed to accumulate, modulate, and make use of endogenous clotting factors in patients to form hemostatic plugs when it matters most.

Register To Buy and Sell Shares

For more details on financing and valuation for Hemab Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Hemab Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Hemab Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Benny Sørensen Ph.D
Chief Executive Officer
Mads Behrndt
Chief Financial Officer
Johan Faber Ph.D
Co-Founder & Chief Technology Officer
Thomas Stenfeldt
Co-Founder

Board Members

Camilla Hansen Ph.D
Novo Holdings
Dan Becker Ph.D
Access Biotechnology
Uya Chuluunbaatar Ph.D
Avoro Ventures

Frequently Asked Questions About Hemab Therapeutics’ Stock

plusminus
Can you buy Hemab Therapeutics’ stock?
Hemab Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Hemab Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Hemab Therapeutics’ stock?
Yes, you can sell stock of a private company like Hemab Therapeutics. Forge can help you sell your Hemab Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Hemab Therapeutics’ stock price?
Hemab Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Hemab Therapeutics’ private market stock price with Forge Data.
plusminus
What is Hemab Therapeutics’ stock ticker symbol?
Hemab Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

With $135M in fresh funds, Hemab aims to leapfrog drug development for neglected blood disorders
While hemophilia has soaked up clinical attention and investor dollars for decades, it’s come at the expense of a range of intriguingly named but less well-known blood clotting disorders. That’s where Hemab Therapeutics comes in.
Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia
Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann Thrombasthenia (Glanzmann).
Updated on: Apr 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.